comparemela.com

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States ,Naomi Eichenbaum ,Deric Dube ,Jula Inrig ,Nivi Nehra ,Travere Therapeutics Inc ,Nasdaq ,European Medicines Agency ,European Union ,Exchange Commission On ,Corporate Communications ,Company Annual Report On Form ,Wall Street ,Dual Endothelin Angiotensin Receptor Antagonist ,New Drug Application ,Conditional Marketing Authorization ,Efficacy Endpoints ,Two Year Exploratory Endpoints ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Travere Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,

comparemela.com © 2020. All Rights Reserved.